# Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

> **NCT04228042** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Renal Pelvis and Ureter Urothelial Carcinoma

## Interventions

- **DRUG:** Infigratinib
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT04228042
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-28
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-04-17
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND
- **Last updated:** 2025-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04228042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04228042, "Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04228042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*